Tg511-08-01: A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511 in Patients With Recurrent High Grade Glioma

Cancer - Brain
  • At least 18 years of age
  • Single, supratentorial HGG (WHO grade III or IV) less than or equal to 9 cm^2 in its greatest cross sectional area
  • At least one surgical gross-total or subtotal resection
  • Postoperative radiation with concurrent temozolomide
Tiffany Pearce